Literature DB >> 18308914

Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophrenia.

Baojin Zhu1, Haya Ascher-Svanum, Lizheng Shi, Douglas Faries, William Montgomery, Stephen R Marder.   

Abstract

OBJECTIVE: This study compared the time to discontinuation for any reason of first-generation antipsychotics--in oral versus depot formulation--in the usual care of schizophrenia.
METHODS: This study used data from a three-year, prospective, nonrandomized, noninterventional, multisite study of schizophrenia. Participants initiated on oral haloperidol or fluphenazine (N=202) were compared with those initiated on haloperidol or fluphenazine in depot formulation (N=97) on time to all-cause discontinuation for one year after initiation, by using Kaplan-Meier survival analysis, a Cox proportional hazards regression model, and propensity score-adjusted bootstrap resampling methods.
RESULTS: Compared with participants treated with the oral formulation, those treated with depot first-generation antipsychotics had a significantly longer mean time to all-cause medication discontinuation and were twice as likely to stay on the medication.
CONCLUSION: In the usual care of schizophrenia, treatment with first-generation antipsychotics in depot formulation appears to be associated with longer time to all-cause medication discontinuation compared with oral formulation of the same medication.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18308914     DOI: 10.1176/ps.2008.59.3.315

Source DB:  PubMed          Journal:  Psychiatr Serv        ISSN: 1075-2730            Impact factor:   3.084


  26 in total

1.  Effectiveness of sulpiride in adult patients with schizophrenia.

Authors:  Edward Chia-Cheng Lai; Chia-Hsien Chang; Yea-Huei Kao Yang; Swu-Jane Lin; Chia-Yin Lin
Journal:  Schizophr Bull       Date:  2012-02-07       Impact factor: 9.306

Review 2.  The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.

Authors:  Sofia Brissos; Miguel Ruiz Veguilla; David Taylor; Vicent Balanzá-Martinez
Journal:  Ther Adv Psychopharmacol       Date:  2014-10

3.  A Reasonable Alternative to Clozapine in the Chronically Relapsing Smoking Patient? A Retrospective Analysis.

Authors:  John R Tomko; Nadeem Ahmed; Cynthia Kuntz; Justine Zick
Journal:  Hosp Pharm       Date:  2016-11

4.  Comparative effectiveness of long-acting risperidone in New Zealand: a report of resource utilization and costs in a 12-month mirror-image analysis.

Authors:  Christopher Carswell; Amanda Wheeler; Jane Vanderpyl; Elizabeth Robinson
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

5.  Duration of pharmacotherapy with long-acting injectable risperidone in the treatment of schizophrenia.

Authors:  Somaia Mohamed; Robert Rosenheck; Ilan Harpaz-Rotem; Douglas Leslie; Michael J Sernyak
Journal:  Psychiatr Q       Date:  2009-09-19

6.  Persistence with pharmacological treatment in the specialist mental healthcare of patients with severe mental disorders.

Authors:  Valentino Conti; Antonio Lora; Andrea Cipriani; Ida Fortino; Luca Merlino; Corrado Barbui
Journal:  Eur J Clin Pharmacol       Date:  2012-05-10       Impact factor: 2.953

7.  Treatment discontinuation and clinical outcomes in the 1-year naturalistic treatment of patients with schizophrenia at risk of treatment nonadherence.

Authors:  Katarina Kelin; Timothy Lambert; Alan Jm Brnabic; Richard Newton; Wendy Ye; Raúl I Escamilla; Kuang-Peng Chen; Liana Don; William Montgomery; Jamie Karagianis; Haya Ascher-Svanum
Journal:  Patient Prefer Adherence       Date:  2011-05-09       Impact factor: 2.711

8.  Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia.

Authors:  Jennifer Kern Sliwa; Cynthia A Bossie; Dong-Jing Fu; Ibrahim Turkoz; Larry Alphs
Journal:  Neuropsychiatr Dis Treat       Date:  2012-08-27       Impact factor: 2.570

9.  Management of antipsychotic treatment discontinuation and interruptions using model-based simulations.

Authors:  Mahesh N Samtani; John J Sheehan; Dong-Jing Fu; Bart Remmerie; Jennifer Kern Sliwa; Larry Alphs
Journal:  Clin Pharmacol       Date:  2012-07-16

10.  Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review.

Authors:  Simon Zhornitsky; Emmanuel Stip
Journal:  Schizophr Res Treatment       Date:  2012-02-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.